Latest Breaking News On - Stoke therapeutics company profile - Page 2 : comparemela.com

Stoke Therapeutics, Inc (NASDAQ:STOK) Receives Consensus Rating of Moderate Buy from Brokerages

Stoke Therapeutics, Inc (NASDAQ:STOK) Receives Consensus Rating of Moderate Buy from Brokerages
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United statesCapital partnersStoke therapeutics incJpmorgan chase coSecurities exchange commissionMirae asset global investments coStoke therapeutics company profileCantor fitzgeraldStoke therapeuticsGet free reportSkorpios trustExchange commissionAsset global investmentsTrexquant investmentGet freeStoke therapeutics daily

Stoke Therapeutics (NASDAQ:STOK) Given New $20 00 Price Target at Canaccord Genuity Group

Stoke Therapeutics (NASDAQ:STOK) Given New $20 00 Price Target at Canaccord Genuity Group
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United statesCantor fitzgeraldSecurities exchange commissionSg americas securitiesDorsey whitney trustJpmorgan chase coSherbrooke park advisersCorton capital incStoke therapeutics incCanaccord genuity groupStoke therapeutics company profileStoke therapeuticsGet free reportGenuity groupExchange commissionSkorpios trust

Stoke Therapeutics (NASDAQ:STOK) Price Target Lowered to $20 00 at Canaccord Genuity Group

Stoke Therapeutics (NASDAQ:STOK) Price Target Lowered to $20 00 at Canaccord Genuity Group
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United statesStephenj tulipanoMirae asset global investments coSecurities exchange commissionCantor fitzgeraldCorton capital incJpmorgan chase coStoke therapeutics incCapital partnersCanaccord genuity groupStoke therapeutics company profileStoke therapeuticsGet free reportGenuity groupExchange commissionAsset global investments

Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 4 4%

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report)’s share price traded down 4.4% during trading on Monday . The company traded as low as $11.36 and last traded at $11.52. 569,902 shares changed hands during trading, a decline of 41% from the average session volume of 971,281 shares. The stock had previously closed at $12.05. […]

United statesJonathan allanSg americas securitiesStoke therapeutics incMirae asset global investments coStoke therapeutics company profileCanaccord genuity groupSherbrooke park advisersYork mellon corpCantor fitzgeraldJpmorgan chase coDorsey whitney trustNeedham companyStoke therapeuticsGet free reportGenuity group

Stoke Therapeutics (NASDAQ:STOK) Trading 4 9% Higher

Stoke Therapeutics (NASDAQ:STOK) Trading 4 9% Higher
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesBarry tichoJpmorgan chase coCapital partnersStoke therapeutics company profileStoke therapeutics incSecurities exchange commissionNeedham companyCanaccord genuity groupStoke therapeuticsGet free reportGenuity groupSkorpios trustExchange commissionSeven grand managersStoke therapeutics daily